Early Results From Islet Cell Transplant Study Show Promise for Type 1 Diabetes

Researchers are exploring whether transplanted insulin-producing cells could help people with Type 1 diabetes produce their own insulin again. A small early study presented recent results worth understanding.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

A small study of islet cell transplantation showed that 10 out of 12 participants continued producing some of their own insulin after the procedure
This is an early-stage result from a small group of people—much more research is needed to understand safety, durability, and who might benefit
Researchers continue working on multiple approaches to potentially delay or reduce Type 1 diabetes progression
This type of research represents a shift toward exploring whether some people with Type 1 could reduce or change their insulin dependence, not a cure for everyone

What Happened in This Study

Vert.Ex Pharmaceuticals presented results from a small study of islet cell transplantation at the American Diabetes Association scientific sessions. Islet cells are the insulin-producing cells in the pancreas that stop working in Type 1 diabetes.

In this study, 12 people with Type 1 diabetes received a transplant of these cells delivered through the portal vein. According to the presentation, 10 of the 12 participants continued to produce some of their own insulin after the procedure.

Why This Matters—And What It Doesn't Mean Yet

For people newly diagnosed with Type 1 diabetes, learning you'll need insulin injections or a pump for life can feel overwhelming. Research exploring whether transplanted cells could restore some insulin production represents a different approach worth following.

However, it's important to be clear about what early results mean. This is a very small study—12 people is not enough to draw broad conclusions. We don't yet know how long the transplanted cells continue working, whether this approach works equally well for all people, what risks might emerge, or how this fits into standard diabetes care.

The Bigger Picture in Type 1 Diabetes Research

This islet cell study is one of many research efforts underway in the U.S. and internationally aimed at changing how Type 1 diabetes is managed or prevented. Researchers are exploring different strategies—some focused on delaying disease onset, others on preserving remaining beta cell function, and still others on replacing insulin-producing cells.

As with any emerging therapy, results need to be confirmed in larger studies, published in peer-reviewed journals, and tested across diverse populations before they can guide treatment decisions.

What to Do Now

If you or a loved one has Type 1 diabetes, continue working with your healthcare team on current management strategies. Stay informed about research progress, but be cautious about early-stage claims. Reputable sources like the American Diabetes Association, JDRF, and peer-reviewed medical journals are good places to track emerging therapies as they move through research phases.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.